H.B. No. 4014 is a bill that mandates the Health and Human Services Commission (the "Commission") to conduct a study on the use of psychedelic therapies, specifically MDMA, psilocybin, and ketamine, for treating conditions such as post-traumatic stress disorder (PTSD) and depression. The study will involve a comprehensive review of clinical trials, current literature, and FDA actions related to these therapies. Additionally, the Commission is tasked with evaluating treatment guidelines and patient access to these therapies, recommending necessary legislative actions to ensure accessibility following FDA approval.

The bill also allows the Commission to seek federal funds and donations to support the study and requires a report to be submitted by December 1, 2026, detailing the study's findings and recommendations. The Act is set to expire on September 1, 2027, and the Commission is only required to implement its provisions if the legislature appropriates specific funding for that purpose. The bill is scheduled to take effect on September 1, 2025.